Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program
- PMID: 21502251
- DOI: 10.1542/peds.2010-1722L
Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program
Abstract
The effort to vaccinate the US population against the 2009 H1N1 influenza virus hinged, in part, on public confidence in vaccine safety. Early in the vaccine program, >20% of parents reported that they would not vaccinate their children. Concerns about the safety of the vaccines were reported by many parents as a factor that contributed to their intention to forgo vaccination (see www.hsph.harvard.edu/news/press-releases/2009-releases/survey-40-adults-absolutely-certain-h1n1-vaccine.html and www.med.umich.edu/mott/npch/reports/h1n1.htm). The safety profiles of 2009 H1N1 monovalent influenza vaccines were anticipated to be (and have been) similar to those of seasonal influenza vaccines, for which an excellent safety profile has been demonstrated. Here we describe steps taken by the US government to (1) assess the key federal systems in place before 2009 for monitoring the safety of vaccines and (2) integrate and upgrade those systems for optimal vaccine-safety monitoring during the 2009 H1N1 monovalent influenza vaccination program. These efforts improved monitoring of 2009 H1N1 vaccine safety, hold promise for enhancing future national monitoring of vaccine safety, and may ultimately help improve public confidence in vaccines.
Similar articles
-
Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy.Expert Rev Vaccines. 2012 Aug;11(8):911-21. doi: 10.1586/erv.12.72. Expert Rev Vaccines. 2012. PMID: 23002972 Review.
-
Safety of pandemic H1N1 vaccines in children and adolescents.Vaccine. 2011 Oct 6;29(43):7559-71. doi: 10.1016/j.vaccine.2011.08.016. Epub 2011 Aug 5. Vaccine. 2011. PMID: 21821086 Review.
-
Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance.Vaccine. 2011 Jun 10;29(26):4378-87. doi: 10.1016/j.vaccine.2011.04.005. Epub 2011 Apr 16. Vaccine. 2011. PMID: 21501644
-
Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.Vaccine. 2010 Oct 21;28(45):7248-55. doi: 10.1016/j.vaccine.2010.09.021. Epub 2010 Sep 16. Vaccine. 2010. PMID: 20850534
-
Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.MMWR Morb Mortal Wkly Rep. 2009 Dec 11;58(48):1351-6. MMWR Morb Mortal Wkly Rep. 2009. PMID: 20010511
Cited by
-
Vaccine Preparedness for the Next Influenza Pandemic: A Regulatory Perspective.Vaccines (Basel). 2022 Dec 13;10(12):2136. doi: 10.3390/vaccines10122136. Vaccines (Basel). 2022. PMID: 36560546 Free PMC article.
-
Guillain-Barré Syndrome Following Influenza Vaccines Affords Opportunity to Improve Vaccine Confidence.J Infect Dis. 2021 Feb 13;223(3):355-358. doi: 10.1093/infdis/jiaa544. J Infect Dis. 2021. PMID: 33137189 Free PMC article. No abstract available.
-
Planning for COVID-19 vaccines safety surveillance.Vaccine. 2020 Sep 11;38(40):6194-6198. doi: 10.1016/j.vaccine.2020.07.013. Epub 2020 Jul 10. Vaccine. 2020. PMID: 32684499 Free PMC article.
-
Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.Vaccine. 2016 Aug 17;34(37):4406-14. doi: 10.1016/j.vaccine.2016.07.019. Epub 2016 Jul 19. Vaccine. 2016. PMID: 27449076 Free PMC article.
-
Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention.Expert Opin Drug Saf. 2016 Sep;15(9):1175-83. doi: 10.1080/14740338.2016.1194823. Epub 2016 Jun 16. Expert Opin Drug Saf. 2016. PMID: 27268157 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
